Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Clenbuterol (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions
Most Recent Events
- 26 Mar 2025 Planned initiation date changed from 1 Feb 2025 to 1 Apr 2025.
- 17 Jun 2024 New trial record